AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Smith & Nephew plc
Video analysis: SNN
All videosNo video analysis for this stock yet. Request one from our team.
News: SNN
Smith & Nephew SNATS (NYSE:SNN) Hits New 52-Week Low Following Analyst Downgrade
Smith and Nephew SNATS, Inc. (NYSE: SNN - Get Free Report) hit a new 52-week low on Wednesday after Bank of America downgraded the stock from a buy rating to a neutral rating. The company traded as low as $27.57 and last traded at $27.8350, with a volume of 3636722 shares changing hands. The stock had
Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m
Smith+Nephew announces cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 8, 2026 / Smith+Nephew, the global medical technology company (the "Company") (LSE:SN)(NYSE:SNN), announces today an offer to purchase for cash (the "Tender Offer"), upon the terms and subject to the conditions set forth in an offer to purchase dated September 8, 2026 (the "Offer to Purchase"), up to U.S.$250 million aggregate principal amount (the "Maximum Tender Amount") of the Company's 2.032% Senior Notes due 2030 (the "Notes") from each registered holder of the Notes (each a "Holder" and collectively, the "Holders"). Capitalized terms not otherwise defined in this announcement have the same meaning as assigned to them in the Offer to Purchase.
Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism
Smith & Nephew PLC (LSE:SN) drew a cautious assessment from Jefferies on Friday, with the broker maintaining its 'buy' rating despite investor scepticism over execution and a reduced financial year 2026 guidance. Shares in the company traded around 1,059p as Jefferies held its 1,500p price target, citing an all-time low valuation of 12 times estimated 2027 earnings alongside lumpy operational execution.
Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit
Panmure Liberum has cut its target price for Smith & Nephew PLC (LSE:SN), the medical devices maker, to 1120p from 1250p, while maintaining its 'hold' rating. The broker said it still struggled to make a credible investment case after a disappointing second quarter and the departure of chief financial officer John Rogers, who is leaving to become CFO of Baxter.
UBS cuts Smith & Nephew target on competitive threats to three franchises
UBS has cut its price target on Smith & Nephew PLC (LSE:SN) to 1,120p from 1,300p, warning that even the medical device group's recently reduced guidance for this year remains at risk. The neutral rating is unchanged, with the new target implying about 3.5% upside from Monday's close of 1,082p.
BlackRock Inc. Invests $505.32 Million in Smith & Nephew SNATS, Inc. $SNN
BlackRock Inc. acquired a new stake in shares of Smith and Nephew SNATS, Inc. (NYSE: SNN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,056,801 shares of the medical equipment provider's stock, valued at approximately $505,323,000.
SNN Advances Surgical Robotics Through Imperial College Partnership
Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.
Smith & Nephew shares slip on CFO's departure
Smith & Nephew PLC (LSE:SN) share prices weakened around 3% after the company announced that chief financial officer John Rogers will leave the company at the end of September. The medical technology group's shares fell as low as 3.5% in early London trading to around 1,072p against Tuesday's 1,110.5p close.
Similar companies
-
Zimmer Biomet Holdings, Inc.
ZBH
·
New York Stock Exchange
Compare
-
Fresenius Medical Care AG & Co. KGaA
FMS
·
New York Stock Exchange
Compare
-
Medpace Holdings, Inc.
MEDP
·
NASDAQ
Compare
-
Royalty Pharma plc
RPRX
·
NASDAQ
Compare
-
Tempus AI, Inc.
TEM
·
NASDAQ
Compare
-
The Cooper Companies, Inc.
COO
·
NASDAQ
Compare